
B/m/vinci8/data1/riedel/corpora/nyt/nyt/data/2006/09/28/1793263.xml÷


ADTO

prestigiousJJO

advisoryJJO

groupNNO

hasVBZO

putVBNO

itsPRP$O

weightNNO

behindINO

	criticismNNO

thatINO

theDTO

FoodNNPORGANIZATION

andCCORGANIZATION

DrugNNPORGANIZATION
#
AdministrationNNPORGANIZATION

isVBZO

	pitifullyRBO

weakJJO

whenWRBO

itPRPO

comesVBZO

toTOO

removingVBGO

	dangerousJJO

prescriptionNNO

drugsNNSO

fromINO

theDTO

marketNNO
	
..OE‚€€€øÿÿÿÿ&/guid/9202a8c04000641f8000000000018a7c *ORGANIZATION£

LastJJO

weekNNO
	
,,O


aDTO

panelNNO

	appointedVBNO

byINO

theDTO

	InstituteNNPORGANIZATION

ofINORGANIZATION

MedicineNNPORGANIZATION
	
,,O

partNNO

ofINO

theDTO

NationalNNPORGANIZATION

AcademyNNPORGANIZATION

ofINORGANIZATION

SciencesNNPSORGANIZATION
	
,,O

issuedVBDO


aDTO

slewNNO

ofINO

recommendationsNNSO

toTOO


strengthenVBO

theDTO

beleagueredJJO

F.D.A.NNPO

asINO

itPRPO

	strugglesVBZO

toTOO

regulateVBO


aDTO

hugeJJO

arrayNNO

ofINO

medicationsNNSO

whoseWP$O

illJJO

effectsNNSO

	sometimesRBO

showVBPO

upRPO

onlyRBO

afterINO

yearsNNSO

ofINO

wideJJO

useNNO
	
..OEƒ€€€øÿÿÿÿ&/guid/9202a8c04000641f800000000df428fe *ORGANIZATIONE„€€€øÿÿÿÿ&/guid/9202a8c04000641f800000000023d911 
*ORGANIZATION·

TheDTO

	instituteNNO

'sPOSO

reportNNO
	
,,O

whichWDTO

wasVBDO

	requestedVBNO

byINO

theDTO

F.D.A.NNPORGANIZATION
	
,,O

deploresVBZO

theDTO

bigJJO

	imbalanceNNO

betweenINO

theDTO

moneyNNO

andCCO

staffNNO

devotedVBNO

toTOO

	approvingVBGO

newJJO

drugsNNSO

andCCO

theDTO

muchJJO

smallerJJRO

	resourcesNNSO

forINO


monitoringVBGO

drugsNNSO

afterINO

theyPRPO

areVBPO

onINO

theDTO

marketNNO
	
..O…€€€øÿÿÿÿ
 
*ORGANIZATIONÎ

TheDTO

	imbalanceNNO

resultsNNSO

inINO

partNNO

fromINO

theDTO

pharmaceuticalJJO

industryNNO

'sPOSO

	providingVBGO

userNNO

feesNNSO

thatWDTO

payVBPO

forINO


expeditingVBGO

theDTO

approvalNNO

processNNO
	
,,O

butCCO

notRBO

forINO


monitoringVBGO

theDTO

aftereffectsNNSO
	
..OÇ

WorseRBRO

yetRBO
	
,,O

evenRBO

whenWRBO

itPRPO

spotsVBZO


aDTO

problemNNO
	
,,O

theDTO

agencyNNO

hasVBZO

veryRBO

littleJJO

powerNNO

toTOO

regulateVBO

drugsNNSO

onINO

theDTO

marketNNO

unlessINO

thereEXO

isVBZO

overwhelmingJJO

evidenceNNO

thatINO

theyPRPO

areVBPO

unsafeJJO
	
,,O

whichWDTO

isVBZO

seldomRBO

theDTO

caseNNO
	
..Oþ

AlthoughINO

theDTO

nationNNO

isVBZO

miredVBNO

inINO

budgetNNO

deficitsNNSO
	
,,O

theDTO

	instituteNNO

wasVBDO

wiseJJO

toTOO

callVBO

forINO


aDTO

largeJJO

increaseNNO

inINO

	financingNNO

andCCO

	personnelNNSO

forINO

thisDTO

	cruciallyRBO

	importantJJO

	regulatorNNO

ofINO

publicJJO

healthNNO
	
..O¶

IfINO

CongressNNPORGANIZATION

isVBZO

tooRBO

stingyJJO

toTOO

anteVBO

upRPO

moreJJRO

moneyNNO
	
,,O

itPRPO

shouldMDO

atINO

leastJJSO

divertVBO

someDTO

ofINO

theDTO

drugNNO

industryNNO

'sPOSO

userNNO

feesNNSO

toTOO

surveillanceNNO

afterINO


aDTO

drugNNO

'sPOSO

approvalNNO
	
..OE†€€€øÿÿÿÿ&/guid/9202a8c04000641f80000000000f0ca5 *ORGANIZATIONö

TheDTO

panelNNO

callsVBZO

forINO

theDTO

F.D.A.NNPORGANIZATION

toTOO

evaluateVBO

theDTO

safetyNNO

andCCO

effectivenessNNO

ofINO

drugsNNSO

thatWDTO

areVBPO

trulyRBO

newJJO
	
,,O

notRBO

justRBO

copycatsNNSO
	
,,O

atINO

leastJJSO

onceRBO

everyDTO

fiveCDO

yearsNNSO
	
..O‡€€€øÿÿÿÿ *ORGANIZATION©

ItPRPO

wantsVBZO

theDTO

agencyNNO

toTOO

beVBO

givenVBNO

explicitJJO

powerNNO

toTOO

compelVBO

post-marketingJJO

studiesNNSO

andCCO

toTOO

imposeVBO

finesNNSO
	
,,O

injunctionsNNSO

andCCO

withdrawalsNNSO

toTOO

enforceVBO

itsPRP$O

	decisionsNNSO
	
..OÕ

InINO


aDTO

	departureNNO

fromINO

conventionalJJO

wisdomNNO
	
,,O

theDTO

panelNNO

alsoRBO

urgesVBZO

theDTO

F.D.A.NNPORGANIZATION

toTOO

requireVBO

thatINO


aDTO

substantialJJO

majorityNNO

ofINO

theDTO

membersNNSO

ofINO

eachDTO

ofINO

itsPRP$O

advisoryJJO

panelsNNSO

beVBO

freeJJO

ofINO

significantJJO

	financialJJO

involvementNNO

withINO

	companiesNNSO

whoseWP$O

	interestsNNSO

mightMDO

beVBO

affectedVBNO
	
..Oˆ€€€øÿÿÿÿ *ORGANIZATION­

ThatDTO

	undercutsNNSO

theDTO

agencyNNO

'sPOSO

claimsNNSO

thatINO

thereEXO

areVBPO

notRBO

enoughJJO

expertsNNSO

withoutINO

tiesNNSO

toTOO

theDTO

drugNNO

industryNNO
	
..O

	EditorialNNPO